Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CFAP100 divergent transcript (CFAP100-DT) is a long non-coding RNA gene, categorized as a *divergent transcript* due to its orientation and proximity relative to neighboring coding genes such as CCDC37[3][5]. Divergent lncRNAs are typically transcribed from promoters shared with an adjacent protein-coding gene but in the opposite (head-to-head) direction. These lncRNAs contribute to local chromatin remodeling and transcriptional regulation of themselves and neighboring genes, though the precise function of CFAP100-DT remains undetermined[3][5]. Currently, CFAP100-DT is not considered a therapeutic target nor is it associated with drug interactions, disease roles, or biomarkers for therapy selection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CFAP100 divergent transcript (CFAP100-DT).